{{Drugbox
| IUPAC_name = 1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide
| image = 5F-NNE1_structure.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = 
| legal_NZ = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 1445580-60-8
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 118796566
| ChemSpiderID      = 29341632
| smiles            = FCCCCCn1cc(c2c1cccc2)C(=O)Nc1cccc2c1cccc2
| StdInChI          = 1S/C24H23FN2O/c25-15-6-1-7-16-27-17-21(20-12-4-5-14-23(20)27)24(28)26-22-13-8-10-18-9-2-3-11-19(18)22/h2-5,8-14,17H,1,6-7,15-16H2,(H,26,28)
| StdInChIKey       = DJKVOBZLMBHFKX-UHFFFAOYSA-N
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 3T22QDP4D9

<!--Chemical data-->
| C=24 | H=23 | F=1 | N=2 | O=1
| molecular_weight = 374.45 g/mol
}}

'''5F-NNE1''' (also known as '''5F-NNEI''' and '''5F-MN-24''') is an [[indole]]-based [[synthetic cannabinoid]] that is presumed to be a potent [[agonist]] of the [[CB1 receptor|CB<sub>1</sub> receptor]] and has been sold online as a [[designer drug]].<ref>{{cite web | url=http://forendex.southernforensic.org/index.php/detail/index/1237 | title=5F-NNEI | publisher=Southern Association of Forensic Scientists | accessdate=24 July 2015}}</ref><ref>{{cite journal | title=Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA | date=May 2015 | author=Ariane Wohlfarth | author2=Marisol S. Castaneto | author3=Mingshe Zhu | author4=Shaokun Pang | author5=Karl B. Scheidweiler | author6=Robert Kronstrand | author7=Marilyn A. Huestis | journal=The AAPS Journal | volume=17 | issue=3 | pages=660–677 | doi=10.1208/s12248-015-9721-0 | pmid=25721194 | PMC=4406957}}</ref> Given the known metabolic liberation (and presence as an impurity) of [[amantadine]] in the related compound [[APINACA]], it is suspected that metabolic hydrolysis of the amide group of 5F-NNE1 may release [[1-naphthylamine]], a known [[carcinogen]].

==Legality==
Sweden's public health agency suggested classifying 5F-NNE1 as hazardous substance on November 10, 2014.<ref>{{cite web | url=http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/ | title=Cannabinoider föreslås bli klassade som hälsofarlig vara | publisher=Folkhälsomyndigheten | accessdate=24 July 2015}}</ref>

==See also==
{{div col|colwidth=30em}}
* [[5F-ADBICA]]
* [[5F-SDB-006]]
* [[AM-2201]]
* [[FDU-NNE1]]
* [[FUB-144]]
* [[FUB-NNE1]]
* [[MMB-2201]]
* [[NNE1]]
* [[PX-1]]
{{Div col end}}

==References==
{{reflist}}

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Fluoroalkanes]]
[[Category:Indolecarboxamides]]
[[Category:Naphthoylindoles]]


{{cannabinoid-stub}}